Global Typhoid Vi Polysaccharide Vaccine Market Projected to Surpass $13.36 Billion by 2029 with 19% Annual Growth

How Are the key drivers contributing to the expansion of the typhoid vi polysaccharide vaccine market?
The typhoid VI polysaccharide vaccine market is anticipated to experience accelerated growth due to an increase in typhoid cases. Caused by the Salmonella typhi bacteria, typhoid is a potentially deadly infection that typically spreads through contaminated food or beverages. The Typhoid Vi polysaccharide vaccine, which is designed to protect adults and children over the age of 2 from typhoid fever caused by Salmonella enterica serovar Typhi, or S. Typhi, is seeing increasing demand. In fact, in August 2024, the UK Health Security Agency, a government entity based in the UK, reported an uptick in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland between 2021 and 2022. The report showed S. Typhi cases surging from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the surge in typhoid cases is spurring the growth of the typhoid Vi polysaccharide vaccine market.

Get Your Typhoid Vi Polysaccharide Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

What growth opportunities are expected to drive the typhoid vi polysaccharide vaccine market's CAGR through 2034?
In recent times, the market size of the typhoid vi polysaccharide vaccine has witnessed quick expansion. Projected growth indicates an increase in the market size from $5.78 billion in 2024 to $6.77 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 17.1%. The substantial growth during the previous period can be linked to factors including disease prevalence, global health programs, traveler vaccination, immunization initiatives by the government, and vaccine effectiveness and safety.

In the coming years, the market for typhoid vi polysaccharide vaccines is predicted to witness accelerated expansion. Projecting a compound annual growth rate (CAGR) of 18.5%, it is expected to reach $13.36 billion by 2029. The growth during the forecast period is due to wider immunization initiatives, focus on global health policies, epidemiological monitoring, a surge in travel medicine needs, and environmental and societal influences. The key trends for this duration are likely to be investments in research and development, regulatory backing, epidemiological research, and heightened awareness in public health.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

What are the emerging trends shaping the future of the typhoid vi polysaccharide vaccine market?
The development of strategic alliances is a prominent trend emerging in the typhoid Vi polysaccharide vaccine market. Top-tier companies in the market for typhoid Vi polysaccharide vaccine are engaging in partnerships to solidify their market presence. For example, The International Vaccine Institute, an organization based in South Korea that is dedicated to addressing globally significant infectious diseases like cholera, typhoid, shigella, and salmonella, collaborated with US-based Moderna, a biopharmaceutical enterprise, in July 2022. As a result of this collaboration, the first economical oral cholera vaccine was produced, alongside a cutting-edge typhoid conjugate vaccine.

Which growth-oriented segments of the typhoid vi polysaccharide vaccine market are leading the industry's development?
The typhoid vi polysaccharide vaccine market covered in this report is segmented -

1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

What regions are leading the charge in the typhoid vi polysaccharide vaccine market?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the typhoid vi polysaccharide vaccine market?
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

What Is Covered In The Typhoid Vi Polysaccharide Vaccine Global Market Report?

• Market Size Forecast: Examine the typhoid vi polysaccharide vaccine market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the typhoid vi polysaccharide vaccine market for a structured understanding.
• Key Players Overview: Analyze major players in the typhoid vi polysaccharide vaccine market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the typhoid vi polysaccharide vaccine market.
• Segment Contributions: Evaluate how different segments drive overall growth in the typhoid vi polysaccharide vaccine market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the typhoid vi polysaccharide vaccine market.
• Industry Challenges: Identify potential risks and obstacles affecting the typhoid vi polysaccharide vaccine market.
• Competitive Landscape: Review strategic developments in the typhoid vi polysaccharide vaccine market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.